Management of atopic dermatitis by Rasmussen, James E.
Allergy, 1989, 44, Suppl. 9, 108-113 CHAPTER V
Management of atopic dermatitis
JAMES E. RASMUSSEN
Department of Dermatology, The University of Michigan, Ann Arbor, U.S.A.
Previous articles have presented interesting and
tborougb discussions of the immunology of IgE,
nnast cells, T-cells and the basic pharmacology
of atopic dermatitis. Others have described
some aspects of the treatment of atopic dermat-
itis by modification of diet, avoidance of inhal-
ant allergens and psychotherapy.
Tbis review will discuss recent advances in
tberapy of atopic dermatitis (AD) excluding
those presented in other articles. Some of these
therapies are either experimental or somewhat
controversial. However, new therapies sbould
not be tried without first having given standard
tberapy a long and reasonable cbance to suc-
ceed. This is important because AD does not
last forever and many patients with a milder
disease will heal spontaneously.
Atopic dermatitis
Rajka (1) believes that most cases of infantile
atopic dermatitis heal at 2-3 years of age. Pa-
tients witb widespread severe involvement and
those wbo persist past 6 years have a much
worse prognosis. Roth & Kierland (2) conduct-
ed a 20-year follow-up on approximately 200
adult patients. Forty percent of those with mild
AD had cleared but only 29 % of those affected
with severe AD were similarly improved.
Standard therapy
Standard tberapy should be directed toward
controlling tbe dryness, erytbema and pruritus
tbat characterize patients of all ages with AD. I
believe that to ensure compliance, standard
therapy sbould be simple and consist of only
three or four basic items. I insist that patients
comply completely with these directions before
venturing into more difficult therapy. My stan-
dard tberapy includes mild to moderate corti-
costeroids ( 1 % hydrocortisone or 0.025%-
0.1% triamcinolone), frequent bathing, avoid-
ance of harsh soaps, and the liberal use of light
to heavy lubricants depending upon the season
and the patient's tolerance. Topical steroids
should never be applied more than 2-3 times a
day whereas lubricants can be applied as need-
ed for dryness. For patients whose disease is
particularly severe, it is often more effective to
begin with a 1-2 week course of the most potent
topical corticosteroid available tapering to a low
to intermediate potency corticosteroids. This
often gives an immediate burst of relief which
can then be maintained with more moderate
drugs. Pediatricians and other non-dermatol-
ogists frequently err when giving corticosteroids
that are far too mild to obtain any therapeutic
benefit.
Oral antihistamines, in my experience, are
remarkably ineffective for the long-term man-
agement of AD. The initial usefulness is soon
overcome by rapid tolerance and I use them
primarily as sedatives at bedtime.
Tbis is all that I try to accomplish at the first
visit. Giving patients complex instructions for
modification of diet, pet control, means to in-
crease the household humidity, avoidance of
inhalants, avoidance of woolens and major
changes in bathing habits are usually too over-
whelming and confusing to be attempted on the
first visit.
It is much better to insist on compliance with
basic therapy before switching to more ad-
vanced therapy. Lichenified areas are much
more difficult to treat.
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Advanced therapy
Many articles have already discussed most
other aspects of advanced therapy. I will de-
scribe recent advances in the use of ultraviolet
light, degerming the infected skin, use of oil of
evening primrose and EPA, cyclosporine, chlo-
roquin, phosphodiesterase inhibitors and avoid-
ance of the house dust mite.
Advanced therapy 1 - systemic steroids
If the patient does not respond to outpatient
therapy with mild topical steroids, lubricants
and antihistamines, and if the disease appears
inflammatory as opposed to lichenified, I next
consider a short course of oral corticosteroids
(prednisone 1 mg/Kg) for 7-21 days. This drug
is far too toxic to be used on a long-term daily
basis except to those with life-threatening ec-
zema and asthma.
Recently, Atherton's group (3) proposed a
novel method of combining inhaled beclometh-
asone diproprionate plus the same agent given
orally. In a placebo controlled trial, 26 children
with severe atopic eczema responded signifi-
cantly better while receiving active agent than
placebo. Skin involvement improved by about a
half and there was a parallel reduction in itch.
They obtained evidence of only very mild adre-
nal suppression but also believed the drug may
be working at the local level of the gut to
decrease gastrointestinal permeability to anti-
gens.
Advanced therapy 2 - UV light
If topical and systemic corticosteroids along
with lubricants and antihistamines do not pro-
duce a satisfactory response, then the patient
should be admitted to the hospital for a course
of ultraviolet light. Falk (4) evaluated 106 pa-
tients with AD who were given either ultraviolet
B (UVB) or a combination of A and B
(UVAB). In group UVAB, 94% of the 54
patients were in remission after 18 treatments
compared to only 84 % of 52 patients in group
B after 23 treatments. This difference was sta-
tisticeilly significant ( P < 0.01). Of those respon-
ding well to therapy, 30 of 44 in UVB relapsed
within 3 months after the last treatment com-
pared to only 27 of 51 in group UVAB.
Very similar results in a smaller group of
patients were obtained by Midelfart, Stenvold
& Volden (5). Fifty-six patients with severe AD
were treated with UVB alone (33 patients) or a
combination of UVB and UVA (23 patients).
Forty-eight percent of UVAB-treated patients
achieved complete remission compared to 27%
of those treated with UVB alone.
Atherton et al. (6) treated 15 adolescent chil-
dren having severe eczema with psoralen che-
motherapy (PUVA). They used psoralen at a
dose of 0.6 mg/Kg body weight with treatment
administered either two or three times a week.
Patients were treated with one J/cm^ with the
UVA dose gradually increasing by increments
of 0.5-2.0 J/cm^ at intervals of not less than 1
week depending upon skin tolerance and re-
sponse until clearly cured. Fourteen of the 15
patients achieved near clearance which took
from 10-25 weeks (medium 16 weeks). Remis-
sion was induced in 9 children.
Of the 7 children with adequate data, 6 had
growth velocities below the third percentile.
During and after PUVA treatment, all 6 of
these children achieved growth velocities be-
tween the 50th and 97th percentile.
Advanced therapy 3 - role of infection
Acute or flaring AD is frequently considered to
have an infectious component. Numerous stud-
ies have shown that the skin of children with
atopic dermatitis is heavily colonized with coag-
ulase positive Staphylcoccus aureus. Leyden, Mar-
pies & Kligman (7) showed that both the in-
volved and uninvolved skin of patients with
atopic dermatitis were heavily colonized with
coagulase-positive Staphylcoccus aureus. Wet le-
sions of atopic dermatitis carry a tremendous
burden of organisms with lesser amounts being
found in tbe dry, lichenified areas and smaller
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quantities present in clinically normal skin. The
exact role of these organisms in the etiology of
atopic dermatitis is not known for certain but
they may play both an infectious and an allergic
role.
David and Cambridge (8) followed 190 chil-
dren with atopic dermatitis prospectively for 2
'A years. Seventy-six children (40%) had exa-
cerbations of their eczema due to bacterial in-
fection and 25 (15%) resulted in admission to
hospital. Staphylococcus aureus was the most com-
mon recovered organism being found in 97 % of
patients.
Welbourn, Champion and Parish in a series
of three classic papers (9-11) evaluated 122
patients with eczematous dermatitis. They
showed that a high percentage had immediate
or 4-h (Arthus-like) responses to intradermal
skin tests with staphylococcal antigens. In addi-
tion, staphylococcal antigen was shown on the
skin surface and in the dermis indicating percu-
taneous absorption. Approximately 60% of the
patients had circulating anti-staphyloccocal im-
munoglobulin that was thought to participate in
this hypersensitivity reaction.
Lever et al. (12) evaluated 49 patients with
atopic dermatitis in a double-blind placebo
crossover trial of mupirocin, a topical anti-sta-
phylococcal antibiotic. All patients had heavy
colonization of the skin with Staphylococcus aureus
prior to therapy. The bacterial count was signif-
icantly reduced by a 2-week treatment with
topical mupirocin twice a day but not by the
placebo. This was accompanied by significant
reduction in clinical severity which was main-
tained over 4 weeks post-therapy even though
recolonization occurred during this period. De-
spite recolonization, clinical parameters re-
mained improved and no serious side effects
were observed.
Many of the new imidazole group of anti-
fungal agents are also potent antibacterials.
White & Blatchford (13) studied 19 patients
with severe atopic eczema. They were treated
with 2 % miconazole plus 1 % hydrocortisone
cream for 14 days. Seventeen of 19 (89%)
demonstrated a significant improvement and
the combination was rated as better than previ-
ous therapy by 68 % of the patients.
It also is generally accepted that the oral use
of systemic antibiotics is useful for acute, weep-
ing flares of AD, particularly those which ap-
pear to be secondarily infected. There are no
long-term studies on the degree of benefits such
therapy provides and the reader should always
be aware of the potential for development of
resistance following both topical and/or system-
ic therapy. Somewhat limiting the usefulness of
the imidazoles and mupirocin is their relatively
high cost and small package size.
Advanced therapy 4 - dietary supplementation
with eiocosapentenoic acid (EPA) and oil of
evening primrose
Wright & Burton (14) were among the first to
conduct a double-blind, controlled, crossover
study of various doses of oral evening primrose
oil. They evaluated 99 patients with atopic ec-
zema. Sixty adults received either two, four or
six capsules twice daily while 39 children (8
months - 14 years of age) received one or two
capsules twice a day. Each capsule contained
360 mg of linoleic acid and 45 mg of gamma-
linolenic acid. The brand name Elamol was
used throughout this study. In the low-dose
groups in children and adults, no objective im-
provements were noticed but patients did feel
that prutitus was improved compared to place-
bo (P<0.05). In the higher dose groups, Efa-
mol was better than placebo with regard to itch,
scaling and general severity. These responses
were noted most prominently in the adult
groups and less so among children. Adult pa-
tients in the high-dose group noted an overall
improvement in severity of about 43 %. No side
effects were noted. The authors felt that the
mode of action was uncertain but that it might
involve prostaglandin synthesis and the regu-
lation of T-lymphocytes.
A somewhat similar study was carried out by
a Finish group (15). They evaluated 25 patients
with atopic eczema treated with either evening
primrose oil (EPO) (n = 14) or placebo (n = 11)
for 12 weeks. Those patients receiving evening
primrose oil noted a statistically significant re-
duction in the severity and grade of inflamma-
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tion as well as the percentage of body surface
area involved. In addition, they felt less itch
and were perceived to be less dry. EPO caused
a significant rise in the amount of dihomogam-
malinolenic acid but plasma levels of thrombox-
ane and prostaglandins were not changed.
Other authors have not been able to duplicate
these beneficial clinical results (16) and in my
uncontrolled clinical experience with over 50
cases, the results have been unimpressive.
Other authors have studied the effect of die-
tary supplementation with eicosapentenoic acid
in the treatment of atopic dermatits. Bjorneboe
et al. (17) gave 10 g of fish oil (1.8 grams EPA)
versus placebo (olive oil) when treating 31
adults with AD. In a 12-week double-blind ran-
domized trial, 16 patients were given 10 cap-
sules max-EPA daily (1.8 grams EPA) and 15
control patients were given 10 olive oil capsules
a day. Severity scores assessed by the physician
showed no statistically significant difference be-
tween the active and placebo groups. However,
the patient's assessment showed that max-EPA
was better than placebo with regard to itch
(P<0.05), scale (P<0.05) and total symptom
score (P<0.02) . No significant difference was
found between the groups with regard to topical
steroid use during the trial.
Advanced therapy 5 - phosphodiesterase inhibitors
Hanifin et al. (18) have demonstrated that leu-
kocytes from patients with AD show elevated
activity of cAMP phosphodiesterase (PDE).
These investigators feel that high PDE activity
may allow increased IgE production and in-
creased histamine release from basophils and
mast cells. Further, they believe that this is a
basic defect of atopic dermatitis.
To my knowledge there are no controlled
trials of any known systemic PDE inhibitor
since most of these drugs are too toxic for
general use. Baer (19) advocates the use of
papaverine 100 mg 4-6 times daily and believes
that it is effective in decreasing pruritus in
patients with AD. Papaverine is believed to be
a non-toxic, mild vasodilator that has been in
use since 1947. Baer anecdotally noted his ther-
apy of "hundreds of patients with moderately
severe atopic dermatitis" and currently uses the
150 mg time-release capsules twice (and occa-
sionally three times) a day. He believes that it
reduces itching in the majority of AD cases and
in some patients "appears to have a truly strik-
ing effect". Baer notes that papaverine is an
inhibitor of leukocyte PDE levels. Hanifin et al.
(18) showed elevated PDE levels accounting for
increased catabolic breakdown of cAMP which,
in turn, explains the reduced cAMP unrespon-
siveness to histamine and isoproterenol in atop-
ic dermatitis.
Other PDE inhibitors such as caffeine used as
a 30% cream with 0.5% hydrocortisone has
been reported to be more effective than 0.5%
hydrocortisone alone in patients with AD (20).
(Also, see article in this supplement by Hanifin
(pp. 41) on the experimental drug RO20-
1724). I have found the use of papaverine to be
without substantial effect in an uncontrolled
series of 50 children with atopic eczema. I have
also found 30 % caffeine creme to be without
effect in significant atopic eczema.
Advanced therapy 6 - house dust mite allergy
Seventy-five percent of children with AD are
sensitized to the house dust mite by the age of
10. Beck & Hagdrup (21) analyzed 210 patients
with atopic dermatitis and a positive prick test
toward the house dust mite {Dermatophagoides
pteronyssinus) finding a higher prevalence of a
birth in the interval May to November when
compared with the expected distribution. Expo-
sure to the house dust mite is much more
common during these months.
Vickers (22) noted that cell-mediated immu-
nity to house dust mite (HDM) antigen was
demonstrated in 11 of 16 patients with atopic
eczema compared to 2 of 14 controls. He re-
viewed work showing the difficulty in hyposen-
sitizing patients to mite antigen, and empha-
sized his work with avoidance of mite dust
antigen using natamycin (Tymosil). This agent
kills Aspergillus fungi which is the staple food of
the house mite. Vickers believes house dust
mite eczema is related to early morning flares,
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high IgE levels and the 4 + positive RAST test
to house dust mite. It may also be associated
with a respiratory allergy. He treated 11 chil-
dren in an open study in which natamycin was
used throughout the house for a 6-mo period.
Three children showed no change, 3 had a
moderate improvement and the remaining 5
(45%) had a dramatic improvement in both
their skin and respiratory allergies.
Norris et al. (23) showed that house dust mite
could play a role in the pathogenesis of atopic
eczema. Application of house dust mite solution
or control to the anticubital or popliteal fossae
showed a marked delayed local reaction in one-
third of patients with AD to house dust mite
only. Further evidence supporting the role of
HDM in the evolution of AD is the fact that
HDM-specific IgE mirrors disease severity and
several uncontrolled studies showing that HDM
avoidance improves AD.
Advanced therapy 7 - desperation therapy
For patients whose eczema is unresponsive to
topical and intermittent use of oral corticoste-
roids, ultraviolet light and dietary supplements,
systemic cytotoxic agents may be useful. Morri-
son & Schulz (24) treated 9 patients with in-
tractable severe atopic dermatitis. Cyclophos-
phamide was used in a daily dose of 100 mg
and azathioprine was administered in a dose of
50-100 mg daily. Patients were monitored care-
fully for development of leukopenia and throm-
bocytopenia. Eight patients were treated with
cyclophosphamide and 2 patients were subse-
quently given azathioprine. All patients report-
ed remarkable improvement in an average of
3'/4 mo. Percent skin involvement which before
therapy had averaged 80 % fell to an average of
7 % involvement during therapy. After the
drugs were stopped, remissions varied from 1-
60 months (average 24 mo).
I have no experience with this drug in adults
or children. Doring & Kreppel (25) treated 62
patients suffering from AD with chloroquin
125-250 mg/day for 3-6 months. In 46 patients
tbe therapy resulted in such significant im-
provement that all systemic and other topical
therapy could be discontinued. Eight other pa-
tients reported substantial improvement but still
used topical corticosteroids.
Hanifin's group (26) evaluated 18 AD pa-
tients who were treated with three times weekly
injections of 50 mg TP-5 or placebo. Younger
patients (< 34 y) responded to TP-5 with much
greater improvement in severity scores than
TP-5 treated patients > 34 y or to placebo
patients of either age group {P< 0.05). Immun-
ological abnormalities also reverted towards
normal in those patients given TP-5.
In a similar study. Harper et al. (27) used
Thymostimulin (TP-1) in a double-blind con-
trolled study of 29 adults with severe life-long
AD. Treatment consisted of two weekly in-
jections of TP-1 1.5 mg/Kg for 10 weeks. They
noted a 20 % reduction in clinical severity when
TP-1 was compared to placebo. T8 lympho-
penia, hyper IgE levels and high blood eosi-
nophilia were unchanged in spite of the clinical
improvement.
Finally I would like to speak about the der-
matological applications of cyclosporine. Van-
joost et al. (28) were the first to note the bene-
ficial effects of cyclosporine on severe AD. They
reported 2 patients with severe drug-resistant
disease were treated with 5 mg/Kg/day of cy-
closporine. Near complete remission (greater
than 90 %) was observed in both cases after 4
weeks of therapy. There was no correlation
between trough blood levels and degree of im-
provement. After discontinuation of cyclospo-
rine, a gradual recurrence of lesions and prur-
itus was observed within 3 weeks.
At The University of Michigan we have
treated a further 5 patients with low-dose cy-
closporin and have noted similarly good re-
sponses with a minimal amount of side effects.
A double-blind controlled study is now under-
way in our institution on low-dose cyclosporin
therapy in the treatment of AD. No pediatric
patients, to my knowledge, have been treated
with this drug, however.
De Prost reported on his recent study of
topical cyclosporine at the Third International
Symposium on Atopic Dermatitis held in Oslo,
Norway. This was a 20 patient, double-blind,
controlled, paired comparison of a 10% topical
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cyclosporine gel. Patients were evaluated at 14
days for pruritus, erythema, lichenification,
and scale xerosis. De Prost reported that all
parameters improved in a statistically signif-
icant fashion and that blood levels of cyclospo-
rin were undetectable at topical dosing levels of
10 mg/Kg.
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